Skip to main content
. 2009 Apr 20;113(25):6304–6314. doi: 10.1182/blood-2008-10-186601

Figure 5.

Figure 5

Emergence of activated CD4+ and CD8+ T cells after rhIL-7 administration. Activated CD4+ and CD8+ T cells (HLA-DR+CD38+) increased on days 1 and 4 after rhIL-7 administration but remained unchanged in placebo recipients. ● represents placebo participants (Inline graphic) and ▲ represets rhIL-7 participants (Inline graphic).